A Phase 3, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Samelisant Compared to Placebo in Patients With Narcolepsy With or Without Cataplexy
Latest Information Update: 24 Apr 2026
At a glance
- Drugs Samelisant (Primary)
- Indications Cataplexy
- Focus Registrational; Therapeutic Use
- Sponsors Suven Life Sciences
Most Recent Events
- 24 Apr 2026 New trial record